Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor T (STAR-T) Cells for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT05631912 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT05631912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05631912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor T (STAR-T) Cells for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2023
Completion date
December 15, 2025
Enrollment
38 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma,b cell